In a reply to questions from the European Ombudsman, the European Medicines Agency (EMA) has published its reasons for agreeing to keep clinical trial information hidden. In 2013, the EMA received requests for documents from clinical trials on the medicine Humira. AbbVie, the manufacturer of Humira, sued the EMA to prevent those documents from being released. In a settlement last year, the EMA agreed to redact some information from those documents. Emily O’Reilly, the European Ombudsman, decided to investigate whether those redactions were legal and in October asked the EMA to explain the redactions.